GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    In: The Lancet, Elsevier BV, Vol. 400, No. 10363 ( 2022-11), p. 1607-1617
    Type of Medium: Online Resource
    ISSN: 0140-6736
    RVK:
    Language: English
    Publisher: Elsevier BV
    Publication Date: 2022
    detail.hit.zdb_id: 2067452-1
    detail.hit.zdb_id: 3306-6
    detail.hit.zdb_id: 1476593-7
    SSG: 5,21
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    Online Resource
    Online Resource
    American Association for Cancer Research (AACR) ; 2014
    In:  Cancer Research Vol. 74, No. 19_Supplement ( 2014-10-01), p. 4114-4114
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 74, No. 19_Supplement ( 2014-10-01), p. 4114-4114
    Abstract: Hypoxia (low oxygen conditions) in prostate tumors is associated with aggressive phenotype and poor prognosis. Also, hypoxia is considered the first major challenge faced by growing mass of neoplastic cells, as cells in hypoxic areas are surrounded by metabolic waste, acidic pH and necrotic cells. To overcome these hostile conditions, tumor cells activate transcriptional machinery leading to neo-angiogenesis, altered metabolism and selection of resistant clones. This suggests that prostate cancer (PCa) growth and progression could be prevented via targeting hypoxia-induced signaling. Here, we analyzed silibinin effect on hypoxia-induced proliferation, angiogenesis and metabolic changes in human PCa cells both in vitro and in vivo. Silibinin inhibited LNCaP cells clone formation (exposed to 1% O2 for 48 hrs and then returned to normoxic culture conditions) by 90-100% at 25-50 µM doses. Under similar hypoxic conditions in 22Rv1 cells, silibinin inhibited the clone formation by 63-77% at 25-50 µM doses. Importantly, conditioned media collected from PCa cells under hypoxic conditions (1% O2 for 24 hrs) induced tube formation by human umbilical vein endothelial cells (HUVEC) on matrigel, whereas conditioned media from silibinin-treated hypoxic PCa cells or silibinin addition in hypoxic-conditioned media abrogated HUVEC tube formation. Interestingly, we observed higher lipid accumulation in LNCaP cells under hypoxia, which was decreased (∼70%) by silibinin. Molecular analyses showed that silibinin decreases hypoxia-induced HIF-1α expression without affecting HIF-1β in PCa cells. Furthermore, silibinin increased the level of FIH (factor inhibiting HIF) and prolyl-hydroxylase 2, involved in HIF-1α degradation. Also, silibinin decreased the level of phosphorylated mTOR and ERK1/2 in PCa cells under hypoxia, and strongly inhibited lipid synthesis via activating AMP-activated protein kinase and decreasing acetyl Co A carboxylase, fatty acid synthase, acetyl Co A synthetase, fatty-acyl Co A synthetase and lipin expression. In vivo, silibinin effect on hypoxia-induced proliferation, angiogenesis and metabolism was analyzed in 22Rv1 xenograft model. Mice with established 22Rv1 tumors were imaged at base-line as well as 6 and 15 days following silibinin administration (200 mg/kg body weight) by diffusion weighted (DWI), dynamic contrast enhanced (DCE)-MRI and 18FDG-PET. At the study end, endogenous tumor metabolites were assed by NMR and various biomarkers by IHC. In vivo results showed that silibinin feeding reduced the tumor volume (by 47%), inhibited HIF-1α signaling, decreased proliferation and angiogenesis (DCE-MRI), induced apoptotic death and modulated tumor metabolism (PET and NMR). Together, these findings further support silibinin usefulness in PCa prevention through inhibiting hypoxia-induced proliferation, angiogenesis and lipogenesis. Citation Format: Gagan Deep, Anand M. Ramteke, Dhanya K. Nambiar, Anil K. Jain, Natalie J. Serkova, Chapla Agarwal, Rajesh Agarwal. Silibinin inhibits hypoxia-induced proliferation, angiogenesis and lipogenesis in prostate cancer cells both in vitro and in vivo. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 4114. doi:10.1158/1538-7445.AM2014-4114
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2014
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 3
    In: Journal of the American College of Cardiology, Elsevier BV, Vol. 67, No. 4 ( 2016-02), p. 379-389
    Type of Medium: Online Resource
    ISSN: 0735-1097
    RVK:
    Language: English
    Publisher: Elsevier BV
    Publication Date: 2016
    detail.hit.zdb_id: 1468327-1
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 4
    Online Resource
    Online Resource
    Elsevier BV ; 2008
    In:  The American Journal of Surgery Vol. 196, No. 2 ( 2008-08), p. 149-154
    In: The American Journal of Surgery, Elsevier BV, Vol. 196, No. 2 ( 2008-08), p. 149-154
    Type of Medium: Online Resource
    ISSN: 0002-9610
    RVK:
    Language: English
    Publisher: Elsevier BV
    Publication Date: 2008
    detail.hit.zdb_id: 2003374-6
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 5
    Online Resource
    Online Resource
    American Association for Cancer Research (AACR) ; 2013
    In:  Cancer Research Vol. 73, No. 3_Supplement ( 2013-02-01), p. C73-C73
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 73, No. 3_Supplement ( 2013-02-01), p. C73-C73
    Abstract: Bone metastasis of prostate cancer (PCA) cells is the main cause of high mortality and morbidity in patients. Recent studies have suggested that cancer stem cells not only sustain the growth and heterogeneity of primary tumors but also play a role in metastasis. Therefore, a better molecular understanding of metastatic cancer stem cells could be exploited towards targeting bone metastasis. Here, we analyzed the role of E-cadherin and Src-beta catenin-SNAI1 axis in regulating the stemness and bone metastasis of PCA cells. Human PCA PC3 cells were transfected with shRNA specific for E-cadherin or random shRNA, and selected for stable knock-down of E-cadherin (ShEC-PC3) or respective control cells (Sh-PC3). MTT, clonogenic and xenograft assays were performed to compare the in vitro and in vivo proliferation potential of Sh-PC3 and ShEC-PC3 cells. Stem cell population was characterized by FACS and prostasphere formation. Orthotopic xenograft model and optical imaging tools were employed to study metastasis. Immunoblotting and immunohistochemistry (IHC) methods were used to analyze proliferation, stemness, EMT, and osteomimicry biomarkers. Our results showed that ShEC-PC3 cells possessed mesenchymal phenotype, enhanced invasiveness and clonogenicity as well as higher growth rate both in cell culture and xenografts. Importantly, compared to Sh-PC3 cells, ShEC-PC3 cells formed significantly higher number and bigger sized prostaspheres suggesting an increase in the stem cell population with E-cadherin knock-down. Also, the ShEC-PC3 prostaspheres disintegration in the presence of serum generated bigger mass of attached proliferating cells compared to Sh-PC3. Cell sorting for established PCA stem cell phenotypic markers (CD44highCD24low) confirmed a two-fold increase in stem cell population along with a nine fold higher CD44high/CD44low population in ShEC-PC3 cells compared to Sh-PC3 cells. Immunoblotting and IHC analyses showed that E-cadherin knock-down increased the expression of stemness markers (CD44, Notch1 and Egr-1) as well as EMT and invasivness markers (Vimentin, pSrc-tyr416, beta catenin, NF-kappaB, integrin alpha 5 and beta 3) in both cell culture and xenograft tissues. Next, to define the role of E-cadherin in PCA metastasis, we orthotopically injected Sh-PC3 or ShEC-PC3 cells in the prostate of nude mice and after 4 weeks, imaged the mice using IR-dye (EGF optical probe). Mice injected with ShEC-PC3 cells showed remarkable metastasis to distant organs mainly to the bones, while mice injected with Sh-PC3 cells showed only prostate localized growth. We also observed increased expression of several osteomimicry molecules namely CXCR4, uPA, RANKL and Runx2 in ShEC-PC3 cells in cell culture as well as xenograft tissues. Importantly, we observed a remarkable increase in SNAI1 expression in both cytoplasmic and nuclear fractions from prostaspheres and xenograft tissues of ShEC-PC3 cells. Furthermore, the SNAI1 knock-down by specific siRNA completely inhibited the prostasphere formation, clonogenicity and invasiveness of ShEC-PC3 cells. The SNAI1 inhibition also decreased the level of pSrc-tyr416 and beta catenin in ShEC-PC3 cells suggesting SNAI1 role in regulating the expression of these molecules. Interestingly, inhibition of Src (by dasatinib) or beta catenin (by FH535) also decreased the SNAI1 expression. These results clearly showed that E-cadherin knock-down in PCA cells promotes the formation of Src-beta catenin-SNAI1 axis which then controls the stemness, invasiveness, and metastasis of PCA cells. Therefore, E-cadherin activators and/or Src-beta catenin-SNAI1 repressors could be useful in targeting the PCA stemness and bone metastasis, and lowering the PCA burden. Citation Format: Gagan Deep, Anil K. Jain, Samiha Mateen, Kavitha C. Vijendra, Subhash C. Gangar, Chapla Agarwal, Rajesh Agarwal. Src-beta catenin-SNAI1 axis is critical for the stemness and bone metastasis of E-cadherin-lacking prostate cancer cells. [abstract]. In: Proceedings of the AACR Special Conference on Tumor Invasion and Metastasis; Jan 20-23, 2013; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2013;73(3 Suppl):Abstract nr C73.
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2013
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 6
    In: Clinical Cancer Research, American Association for Cancer Research (AACR), Vol. 10, No. 24 ( 2004-12-15), p. 8641-8647
    Abstract: The acute and cumulative dose-related toxicity and drug resistance, mediated via nuclear factor κB (NFκB), of anthracycline anticancer drugs pose a major problem in cancer chemotherapy. Here, we report that oral silibinin (a flavanone) suppresses human non–small-cell lung carcinoma A549 xenograft growth (P = 0.003) and enhances the therapeutic response (P & lt; 0.05) of doxorubicin in athymic BALB/c nu/nu mice together with a strong prevention of doxorubicin-caused adverse health effects. Immunohistochemical analyses of tumors showed that silibinin and doxorubicin decrease (P & lt; 0.001) proliferation index and vasculature and increase (P & lt; 0.001) apoptosis; these effects were further enhanced (P & lt; 0.001) in combination treatment. Pharmacologic dose of silibinin (60 μmol/L) achieved in animal study was biologically effective (P & lt; 0.01 to 0.001, growth inhibition and apoptosis) in vitro in A549 cell culture together with an increased efficacy (P & lt; 0.05 to 0.001) in doxorubicin (25 nmol/L) combination. Furthermore, doxorubicin increased NFκB DNA binding activity as one of the possible mechanisms for chemoresistance in A549 cells, which was inhibited by silibinin in combination treatment. Consistent with this, silibinin inhibited doxorubicin-caused increased translocation of p65 and p50 from cytosol to nucleus. Silibinin also inhibited cyclooxygenase-2, an NFκB target, in doxorubicin combination. These findings suggest that silibinin inhibits in vivo lung tumor growth and reduces systemic toxicity of doxorubicin with an enhanced therapeutic efficacy most likely via an inhibition of doxorubicin-induced chemoresistance involving NFκB signaling.
    Type of Medium: Online Resource
    ISSN: 1078-0432 , 1557-3265
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2004
    detail.hit.zdb_id: 1225457-5
    detail.hit.zdb_id: 2036787-9
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 7
    In: International Journal of Cancer, Wiley, Vol. 108, No. 5 ( 2004-02-20), p. 733-740
    Abstract: Dietary intake of many fruits and vegetables has been shown to be associated with reduced risk of cancer. We investigated the in vivo efficacy of grape seed extract (GSE, patented as Traconol) against prostate cancer (PCA) and associated molecular events. Athymic nude mice were implanted with hormone‐refractory human prostate carcinoma DU145 cells and fed with 100 and 200 mg/kg/day (5 days/week) doses of GSE for 7 weeks. At the end of experiment, tumors were immunohistochemically analyzed for cell proliferation, apoptosis and angiogenesis. Our data show that GSE feeding strongly inhibited tumor growth that accounted for 59–73% ( p 〈 0.001) inhibition in tumor volume and 37–47% ( p 〈 0.05) decrease in tumor weight at the end of the experiment. It did not show any significant change in body weight gain profile and diet consumption. Immunohistochemical analysis of tumors showed that GSE decreases proliferation index by 51–66% ( p 〈 0.001) and increases apoptotic index by 3–4‐fold ( p 〈 0.001). CD31 staining for endothelial cells, showed decrease in intratumoral microvasculature in GSE‐fed group of mice. Control tumors showed 64.0 ± 1.6 CD31 positive cells/400× field compared to 23.2 ± 0.9 and 15.7 ± 0.08 ( p 〈 0.001) CD31 positive cells in 100 and 200 mg/kg doses of GSE‐treated tumors, respectively. GSE strongly inhibited (47–70%, p 〈 0.05) vascular endothelial growth factor (VEGF) secretion in conditioned medium by DU145 cells. Recently, the circulating level of insulin‐like growth factor binding protein (IGFBP)‐3 is shown to inversely related with PCA risk, growth and prognosis. Consistent with this, we observed 6–7‐fold ( p 〈 0.001) increase in tumor‐secreted levels of IGFBP‐3 after GSE feeding. In other immunohistochemical studies, compared to controls, tumor xenografts from GSE‐fed groups of mice showed a moderate decrease in VEGF but an increase in IGFBP‐3 levels. These findings suggest that GSE possesses in vivo anticancer efficacy against hormone‐refractory human PCA, which is associated with its antiproliferative, proapoptotic and antiangiogenic activities together with upregulation of IGFBP‐3. © 2003 Wiley‐Liss, Inc.
    Type of Medium: Online Resource
    ISSN: 0020-7136 , 1097-0215
    URL: Issue
    RVK:
    Language: English
    Publisher: Wiley
    Publication Date: 2004
    detail.hit.zdb_id: 218257-9
    detail.hit.zdb_id: 1474822-8
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 8
    In: Oncogene, Springer Science and Business Media LLC, Vol. 22, No. 51 ( 2003-11-13), p. 8271-8282
    Type of Medium: Online Resource
    ISSN: 0950-9232 , 1476-5594
    RVK:
    Language: English
    Publisher: Springer Science and Business Media LLC
    Publication Date: 2003
    detail.hit.zdb_id: 2008404-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 9
    Online Resource
    Online Resource
    American Association for Cancer Research (AACR) ; 2012
    In:  Cancer Research Vol. 72, No. 8_Supplement ( 2012-04-15), p. 3426-3426
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 72, No. 8_Supplement ( 2012-04-15), p. 3426-3426
    Abstract: Prostate cancer (PCA) is the most common non-cutaneous cancer and is the second leading cause of cancer-related deaths in American men. Bone metastasis of PCA cells is main cause of high mortality; therefore, a better understanding of the metastatic events might help to develop newer strategies that would lower the PCA burden. Recent studies suggest that cancer stem cell population not only sustains the growth and heterogeneity of the primary tumors but also metastasis. Here, we analyzed the role of E-cadherin, a transmembrane protein, in regulating the ‘stemness’ and ‘bone metastasis’ of PCA cells. First, we transfected human PCA PC3 cells with shRNA specific for E-cadherin or random shRNA, and selected cells with stable knock-down of E-cadherin (ShEC-PC3 cells) and respective control cells (Sh-PC3 cells). ShEC-PC3 cells showed mesenchymal phenotype, shorter doubling time, enhanced invasiveness and clonogenicity. Importantly, compared to Sh-PC3 cells, ShEC-PC3 cells also formed significantly higher number and bigger sized prostaspheres suggesting an increase in the stem cell population with E-cadherin knock-down. Cell sorting for established stem cell phenotypic markers (CD44hiCD24lo) confirmed a two-fold increase in stem cell population along with a nine fold higher CD44hi/CD44lo population in ShEC-PC3 cells compared to Sh-PC3 cells. Western blot analysis showed that E-cadherin knock-down increases the expression of stemness markers (CD44, Notch1 and Egr-1) and EMT markers (Vimentin, phospho-Src, beta-catenin and NF-kB). Importantly, we observed a remarkable increase in SNAI1 expression in cytoplasmic and nuclear fractions with E-cadherin knock-down. We also observed a remarkably higher SNAI1 expression in the prostaspheres formed by ShEC-PC3 cells, and SNAI1 knock-down by specific siRNA completely inhibited the prostaspheres formed by ShEC-PC3 cells, further validating the critical role of SNAI1 in regulating the self-renewal capability of stem cells in ShEC-PC3 cells. Next, to define the role of E-cadherin in PCA metastasis, we orthotopically injected Sh-PC3 or ShEC-PC3 cells in the prostate of nude mice and after 4 weeks, imaged the mice using IR-dye (EGF optical probe). Mice injected with ShEC-PC3 cells showed remarkable metastasis to distant organs mainly to the bones, while mice injected with Sh-PC3 cells showed only prostate localized growth. We also observed increased expression of several molecules that are important in PCA bone metastasis namely CXCR4, uPA, RANKL and Runx2 with E-cadherin knock-down. Overall, these results suggest the important role of E-cadherin in regulating the stemness and bone metastasis of PCA cells, which have significant translational implications as E-cadherin is mostly silenced epigenetically in cancer cells. We conclude that it might be possible to prevent metastasis in PCA patients with localized disease through re-activating E-cadherin expression in PCA cells. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 3426. doi:1538-7445.AM2012-3426
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2012
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 10
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 79, No. 13_Supplement ( 2019-07-01), p. 5088-5088
    Abstract: Non-melanoma skin cancers (NMSCs) account for about half of all malignancies diagnosed annually in the United States. Around 80% of NMSCs are basal cell carcinoma (BCC) and 20% are squamous cell carcinoma (SCC). Whereas the efficacy of several chemopreventive agents has been examined and reported against both BCC and SCC, a majority of these studies have focused on the test agent’s activity in a long-term setting to determine the amount of tumors formed. Notably, the studies evaluating the efficacy of chemopreventive agents during early stage/s of BCC development are lacking. Accordingly, utilizing the well-established patched (Ptch)+/- mouse model of UVB-induced BCC formation, we excised skin samples from UVB exposed mice prior to tumor formation to study the promotion/progression of BCC and to determine the target/s of silibinin, a well-known skin cancer (SCC) chemopreventive agent, in tumor growth inhibition. Ptch+/- and Ptch+/+ mice were irradiated with UVB 240mJ/cm2 3 times per week with or without topically applied silibinin 5 times per week. As early as one month, we found that UVB exposure significantly increased the number of mast cells in Ptch+/- mice by about 48% (P & lt;0.05), which was completely inhibited (to control levels) by silibinin topical treatments. In Ptch+/+ mice, which do not develop BCC tumors, we did not observe any increase in mast cells following UVB exposure, suggesting this could be a specific pathway in the development of BCC. To decipher the molecular mechanism of these findings, we performed a PCR profiler array analysis of several genes involved in signal transduction pathways which showed strong differences between Ptch+/+ and Ptch+/- mice that were unexposed, UVB irradiated, and silibinin treated. Most notably, following UVB exposure for 1 month, in Ptch+/- mice the expression of Bone morphogenetic protein 2 (BMP-2), Hairy/enhancer-of-split related with YRPW motif 1 (Hey1), and Inhibitor of DNA binding 1 (Id1) was significantly upregulated when compared to Ptch+/+ mice. Additional studies focusing on BMP-2 found that silibinin strongly inhibits UVB-induced expression of BMP-2 in Ptch+/- mouse skin. Consistent with these results, we also found that silibinin strongly attenuates UVB-induced BMP-2 expression and DNA damage in Ptch+/- mouse skin ex vivo. Regarding BCC formation, silibinin treatment inhibited UVB-induced microscopic BCC formation in Ptch+/- mice; microscopic tumor number and size were reduced by 73% and 84%, respectively. Together, our results suggest a possible role of BMP-2 in early stages of BCC development and that silibinin plausibly acts through BMP-2 to inhibit microscopic BCC formation. In conclusion, our previous studies in SCC models and current findings in BCC model suggest that silibinin could be a multi-target agent capable of being a chemopreventive agent for both types of NMSCs. Citation Format: Cynthia M. Rigby, Gagan Deep, Anil K. Jain, David J. Orlicky, Chapla Agarwal, Komal Raina, Rajesh Agarwal. Silibinin inhibits UVB-induced promotion and progression of microscopic basal cell carcinoma formation via targeting bone morphogenic protein 2 [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 5088.
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2019
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...